Background: Modern oncology has a compelling problem in predicting the hazards of venous thromboembolism (VTE) linked with chemotherapy. Although thromboprophylaxis is not now advised for primary prevention, it is typically advised that cases' risks of VTE be evaluated before treatment. Great interest was given to establishing effective predictive methods for VTE in cancer cases. The aim of this study: The study aimed to detect whether Egyptian cancer cases' VTE risk could be predicted using the modified Vienna Cancer and Thrombosis Study (CATS) score. Methods: 214 newly diagnosed cancer cases participated in a prospective cohort study completed before receiving chemotherapy. Cases who received chemotherapy were monitored for VTE episodes for six months. The Khorana score was determined. D dimer and soluble P-selectin (sP-selectin) levels were assessed, followed by a modified Vienna CATS score. For each example, the Vienna CATS score was determined. Results: Only 24 (11.2%) of the 214 cases who had follow-up experienced VTE episodes, and 5 of these (2.3%) were lost.  Conclusion: When compared to the Khorana score, the modified Vienna CATS score was more sensitive in identifying cancer cases at risk for VTE. Implementation of modified Vienna CATS in the clinical workup of cancer cases could help physicians to tailor antithrombotic therapy and lead to the perfect use of thromboprophylaxis.